{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:23Z","timestamp":1792791923624,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.critrevonc.2020.103163","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T12:01:44Z","timestamp":1605182504000},"page":"103163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?"],"prefix":"10.1016","volume":"157","author":[{"given":"Gioia","family":"Colafigli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Di Prima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-9284","authenticated-orcid":false,"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Loglisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Diverio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2020.103163_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1373\/clinchem.2016.262824","article-title":"RT-qPCR and RT-Digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia","volume":"63","author":"Alikian","year":"2017","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103163_bib0010","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med."},{"issue":"03","key":"10.1016\/j.critrevonc.2020.103163_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9929.1000330","article-title":"Digital PCR (Dpcr) a step forward to detection and quantification of minimal residual disease (MRD) in ph+\/BCR\u2010ABL1 chronic myeloid leukemia (CML)","volume":"08","author":"Bernardi","year":"2017","journal-title":"J. Mol. Biomark. Diagn."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103163_bib0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/asheducation-2016.1.156","article-title":"Molecular monitoring in chronic myeloid leukemia\u2014how low can you go?","volume":"2016","author":"Branford","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103163_bib0025","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1080\/10428194.2016.1198959","article-title":"Rationale and motivating factors fortreatment-free remission in chronic myeloid leukemia","volume":"57","author":"Caldemeyer","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103163_bib0030","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hon.2650","article-title":"Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome","volume":"37","author":"Colafigli","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103163_bib0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment\u2010free remission with first\u2010 and second\u2010generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2020.103163_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2019-125226","article-title":"Increased tumour burden over a 36 month period in chronic myeloid leukemia patients following imatinib discontinuation: role of digital PCR","volume":"134","author":"Diral","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103163_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103163_bib0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103163_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.critrevonc.2020.103163_bib0060","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1080\/10428194.2019.1590569","article-title":"Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis","volume":"60","author":"Heinrich","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103163_bib0065","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103163_bib0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103163_bib0075","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103163_bib0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecularrelapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.103163_bib0085","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103163_bib0090","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103163_bib0095","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"NCCN guidelines insights: chronic myeloid leukemia, version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103163_bib0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103163_bib0105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/s18041271","article-title":"dPCR: a technology review","volume":"18","author":"Quan","year":"2018","journal-title":"Sensors (Basel)"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103163_bib0110","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103163_bib0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronicmyelogenous leukemia in complete molecular remission for morethan 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.103163_bib0120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103163_bib0125","first-page":"792","article-title":"First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial","author":"Saussele","year":"2014","journal-title":"19th Congress of the European Hematology Association, Milan, Italy, June 12-15"},{"issue":"3","key":"10.1016\/j.critrevonc.2020.103163_bib0130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.13084","article-title":"Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: a high sensitive method of the minimal residual disease and disease progression","volume":"101","author":"Wang","year":"2018","journal-title":"Eur. J. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820302997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:36:36Z","timestamp":1760902596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820302997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":26,"alternative-id":["S1040842820302997"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103163","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103163"}}